Interestingly, studies have shown that the genetic deletion of PPARγ in the livers of lipodystrophic transgenic mice markedly attenuates the development of NAFLD, independent of the presence of hyperinsulinemia or hyperglycemia [50, 51]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.